Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Brain Res ; 1460: 12-24, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22578469

ABSTRACT

Fibroblast growth factor receptor (FGFR) signaling determines the size of the cerebral cortex by regulating the amplification of radial glial stem cells, and participates in the formation of midline glial structures. We show that Fgfr1 and Fgfr2 double knockouts (FGFR DKO) generated by Cre-mediated recombination driven by the human GFAP promoter (hGFAP) have reduced cerebellar size due to reduced proliferation of radial glia and other glial precursors in late embryonic and neonatal FGFR DKO mice. The proliferation of granule cell progenitors (GCPs) in the EGL was also reduced, leading to reduced granule cell numbers. Furthermore, both inward migration of granule cells into the inner granule cell layer (IGL) and outward migration of GABA interneurons into the molecular layer (ML) were arrested, disrupting layer and lobular morphology. Purkinje neurons and their dendrites, which were not targeted by Cre-mediated recombination of Fgf receptors, were also misplaced in FGFR DKO mice, possibly as a consequence of altered Bergmann glia orientation or reduced granule cell number. Our findings indicate a dual role for FGFR signaling in cerebellar morphogenesis. The first role is to amplify the number of granule neuron precursors in the external granular layer and glial precursor cells throughout the cerebellum. The second is to establish the correct Bergmann glia morphology, which is crucial for granule cell migration. The disrupted cerebellar size and laminar architecture resulting from loss of FGFR signaling impair motor learning and coordination in FGFR DKO mice.


Subject(s)
Cerebellar Diseases/genetics , Cerebellar Diseases/pathology , Motor Skills Disorders/pathology , Motor Skills Disorders/physiopathology , Receptor, Fibroblast Growth Factor, Type 1/deficiency , Receptor, Fibroblast Growth Factor, Type 2/deficiency , Animals , Cerebellar Diseases/physiopathology , Female , Humans , Male , Mice , Mice, Knockout , Mice, Neurologic Mutants , Motor Skills Disorders/genetics , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Receptor, Fibroblast Growth Factor, Type 2/metabolism
2.
Biol Psychiatry ; 63(10): 953-62, 2008 May 15.
Article in English | MEDLINE | ID: mdl-17988653

ABSTRACT

BACKGROUND: Motor hyperactivity due to hyper-dopaminergic neurotransmission in the basal ganglia is well characterized; much less is known about the role of the neocortex in controlling motor behavior. METHODS: Locomotor behavior and motor, associative, and spatial learning were examined in mice with conditional null mutations of fibroblast growth factor receptor 1 (Fgfr1) restricted to telencephalic neural precursors (Fgfr1(f/f;hGfapCre)). Locomotor responses to a dopamine agonist (Amphetamine 2 mg/kg and Methylphenidate 10 mg/kg) and antagonists (SCH233390 .025 mg/kg and Haloperidol .2 mg/kg) were assessed. Stereological and morphological characterization of various monoaminergic, excitatory, and inhibitory neuronal subtypes was performed. RESULTS: Fgfr1(f/f;hGfapCre) mice have spontaneous locomotor hyperactivity characterized by longer bouts of locomotion and fewer resting points that is significantly reduced by the D1 and D2 receptor antagonists. No differences in dopamine transporter, tyrosine hydroxylase, or serotonin immunostaining were observed in Fgfr1(f/f;hGfapCre) mice. There was no change in cortical pyramidal neurons, but parvalbumin+, somatostatin+, and calbindin+ inhibitory interneurons were reduced in number in the cerebral cortex. The decrease in parvalbumin+ interneurons in cortex correlated with the extent of hyperactivity. CONCLUSIONS: Dysfunction in specific inhibitory cortical circuits might account for deficits in behavioral control, providing insights into the neurobiology of psychiatric disorders.


Subject(s)
Cerebral Cortex/pathology , Fibroblast Growth Factor 1/genetics , Hyperkinesis/genetics , Hyperkinesis/pathology , Neural Inhibition/genetics , Neurons/pathology , Amphetamine/therapeutic use , Animals , Behavior, Animal/drug effects , Biogenic Monoamines/metabolism , Cell Count/methods , Central Nervous System Stimulants/therapeutic use , Disease Models, Animal , Dopamine Agents/administration & dosage , Exploratory Behavior/drug effects , Fibroblast Growth Factor 1/deficiency , Glutamate Decarboxylase/metabolism , Hyperkinesis/drug therapy , Locomotion/drug effects , Locomotion/genetics , Male , Methylphenidate/therapeutic use , Mice , Mice, Knockout , Motor Activity/drug effects , Motor Activity/genetics , Nerve Tissue Proteins/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics
SELECTION OF CITATIONS
SEARCH DETAIL